Camargo Expands, Opens New Office in The Research Triangle Park
Camargo Pharmaceutical Services, an end-to-end drug development company specializing in the 505(b)(2) process, has announced today its expansion into The Research Triangle Park (RTP) with the opening of a new office. The new location will pave the way for additional opportunities and service offerings, as well as streamlining client service.
Camargo’s decision to expand its reach to the east coast, specifically RTP, abides with the Company’s overall growth goals and global service coverage. RTP, the largest research park in the nation, is a 7,000-acre development that is home to more than 170 companies.
Camargo is focused on global drug development through the 505(b)(2) process and provides a full spectrum of services from discovery through each phase of clinical development.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
